Home > PROTACs

PROTACs

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC50269 DBCO-PEG6-amine TFA DBCO-PEG6-amine (TFA) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
DC50270 TCO-PEG2-Sulfo-NHS ester sodium TCO-PEG2-Sulfo-NHS ester sodium is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
DC50038 PROTAC SGK3 degrader-1 Featured PROTAC SGK3 degrader-1 (SGK3-PROTAC1), is a potent SKG3 degrader based on PROTAC. PROTAC SGK3 degrader-1 (0.3 μM) induces 50% degradation of endogenous SGK3 within 2 hours, with maximal 80% degradation observed within 8 hours, accompanied by a loss of phosphorylation of NDRG1 (an SGK3 substrate).
DC50053 E3 Ligase Ligand-Linker Conjugates 20 Featured Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
DC50055 Thalidomide-NH-C6-NH2 Featured Thalidomide-NH-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
DC50056 Thalidomide-PEG2-C2-NH2 Featured Thalidomide-PEG2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.
DC50057 E3 ligase Ligand-Linker Conjugates 30 Featured E3 ligase Ligand-Linker Conjugates 30 incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a PROTAC linker. E3 ligase Ligand-Linker Conjugates 30 can be used to design PROTAC MDM2 degrader[1].
DC50058 VH032-C3-NH2((S,R,S)-AHPC-C3-NH2) Featured (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852. UNC6852 is an EED-targeted bivalent chemical degrader[1].
DC50059 (S,R,S)-AHPC-C4-NH2 Featured (S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC[1].
DC50060 (S,R,S)-AHPC-C2-NH2 dihydrochloride Featured (S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs[1].
DC50061 Pomalidomide-C2-NH2(E3 ligase Ligand 17) Featured E3 ligase Ligand 17 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 17 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1].
DC50062 Thalidomide-NH-PEG1-C2-NH2 Featured Thalidomide-NH-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
DC50063 (S,R,S)-AHPC-C6-NH2 Featured PROTAC building block.
DC50064 (S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) Featured (S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.
DC50065 （S,R,S)-AHPC-CO-CI-Br Featured （S,R,S)-AHPC-CO-CI-Br is a novel protac building block,
DC50068 (S,R,S)-AHPC-Me-C10-NH2 Featured (S,R,S)-AHPC-Me-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432
DC50069 (S,R,S)-AHPC-PEG4-NH2(E3 ligase Ligand-Linker Conjugates 7) Featured (S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
DC50070 (S,R,S)-AHPC-PEG2-NH2 (E3 ligase Ligand-Linker Conjugates 6 Free Base) Featured (S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
DC50071 (S,R,S)-AHPC-PEG2-NH2 hydrochloride E3 ligase Ligand-Linker Conjugates 6) Featured (S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
DC50072 (S,R,S)-AHPC-PEG3-NH2 （E3 ligase Ligand-Linker Conjugates 5） Featured (S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
DC50073 (S,R,S)-AHPC-PEG3-NH2 hydrochloride（E3 ligase Ligand-Linker Conjugates 5） Featured (S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
DC50074 (S,R,S)-AHPC-Me-C1-NH2 Featured (S,R,S)-AHPC-Me-C1-NH2 is a novel PROTAC Building block.
DC50075 (S,R,S)-AHPC-Me-C2-NH2 Featured (S,R,S)-AHPC-Me-C2-NH2 is a novel PROTAC building block.
DC50076 (S,R,S)-AHPC-Me-C3-NH2 Featured (S,R,S)-AHPC-Me-C3-NH2 is a novel PROTAC building block.
DC50077 (S,R,S)-AHPC-Me-C4-NH2 Featured (S,R,S)-AHPC-Me-C4-NH2 is a novel PROTACA building block.
DC50078 (S,R,S)-AHPC-Me-C8-NH2 Featured (S,R,S)-AHPC-Me-C8-NH2 is a novel PROTAC building block.
DC50079 Thalidomide-O-amido-C5-NH2 Featured Thalidomide-O-amido-C5-NH2 is a novel PROTAC building block.
DC70618 MS177 Featured MS 177 (MS-177) is a potent and selective EZH2 degarder (PROTAC) based on EZH2 inhibitor C24 with CRBN ligand pomalidomide with DC50 of 0.2 uM in EOL-1 cells.MS177 effectively degraded cellular EZH2-PRC2, suppressed global H3K27me3 in leukaemia cells.MS177 exhibited half-maximal degradation concentration (DC50) values of 0.2 ± 0.1 μM and 1.5 ± 0.2 μM, and maximum degradation (Dmax) values of 82% and 68%, respectively, in EOL-1 and MV4;11 cells.MS177 efficiently suppresses EZH2-PRC2 functions, also efficiently induces Myc degradation in cancer cells, suppresses EZH2-PRC2 functions.MS177 efficiently induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest, which is more effective than EZH2 inhibitors. MS177 (i.p. injection, 50-1 g/kg) represses AML growth without apparent toxicity in PDX models.
DC70620 MS934 Featured MS934 (MS-934) is a VHL-recruiting MEK1/2 degrader (PROTAC) with HT29 DC50 of 18/9 nM for MEK1/2 degradation, respectively.MS934 is more potent at inhibiting the growth of HT-29, SK-MEL-28, H3122, and SUDHL1 cells. MS934 also displays good plasma exposure in mice.
DC70621 MS9715 Featured MS9715 (MS-9715) is a NSD3-targeting PROTAC designed by linking BI-9321, a NSD3 antagonist, which binds NSD3's PWWP1 domain, with an E3 ligase VHL ligand.MS9715 achieves effective and specific targeting of NSD3 and associated cMyc node in tumor cells.MS9715 effectively suppresses growth of NSD3-dependent hematological cancer cells.MS 9715 effectively suppresses NSD3-and cMyc-associated gene expression programs, resembling effects of the CRISPR-Cas9-mediated knockout of NSD3.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia